TriangleHEALTH PROFESSIONAL · SOURCE READING
Targeted therapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
In a phase II, single-arm, multicenter study, 41 adult patients with unresectable or metastatic high-grade or intermediate-grade liposarcoma were treated with pazopanib at a dose of 800 mg daily.[28][Level of evidence B4]
Source links and citations
The progression-free survival (PFS) rate at 12 weeks was 68.3%, which was significantly greater than the null hypothesis value of 40%.
Forty-four percent of patients experienced tumor control. One patient had a partial response, and 17 patients had stable disease.
At 24 weeks, 39% of the patients remained progression free. The median PFS was 4.4 months, and median OS was 12.6 months.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice